Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

Brown, David M; Nguyen, Quan Dong; Marcus, Dennis M; Boyer, David S; Patel, Sunil; Feiner, Leonard; Schlottmann, Patricio G; Rundle, Amy Chen; Zhang, Jiameng; Rubio, Roman G; Adamis, Anthony P; Ehrlich, Jason S; Hopkins, J Jill

Brown, David M; Nguyen, Quan Dong; Marcus, Dennis M; Boyer, David S; Patel, Sunil; Feiner, Leonard; Schlottmann, Patricio G; Rundle, Amy Chen; Zhang, Jiameng; Rubio, Roman G; Adamis, Anthony P; Ehrlich, Jason S; Hopkins, J Jill.

Affiliation

Brown DM; Retina Consultants of Houston, The Methodist Hospital, Houston, Texas.

Ophthalmology ; 120(10): 2013-22, 2013 Oct.

Article in En | MEDLINE | ID: mdl-23706949

Subject(s)

Angiogenesis Inhibitors/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Diabetic Retinopathy/drug therapy; Macular Edema/drug therapy; Adult; Diabetic Retinopathy/physiopathology; Female; Humans; Intravitreal Injections; Macular Edema/physiopathology; Male; Ranibizumab; Visual Acuity/physiology

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Macular Edema / Angiogenesis Inhibitors / Diabetic Retinopathy / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials Limits: Adult / Female / Humans / Male Language: En Year: 2013 Type: Article

Fulltext

XML

PubMed Links

Search on Google